Profile data is unavailable for this security.
About the company
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
- Revenue in USD (TTM)520.00k
- Net income in USD-201.40m
- Incorporated1990
- Employees141.00
- LocationGeron Corp919 East Hillsdale Boulevard, Suite 250FOSTER CITY 94404United StatesUSA
- Phone+1 (650) 473-7700
- Fax+1 (302) 655-5049
- Websitehttps://www.geron.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rocket Pharmaceuticals Inc | 0.00 | -249.31m | 2.12bn | 268.00 | -- | 4.79 | -- | -- | -2.87 | -2.87 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -49.16 | -35.26 | -52.49 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0458 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
Arvinas Inc | 71.30m | -354.80m | 2.18bn | 445.00 | -- | 3.58 | -- | 30.61 | -6.05 | -6.05 | 1.22 | 8.93 | 0.0597 | -- | 12.08 | 160,224.70 | -29.59 | -22.01 | -37.90 | -26.47 | -- | -- | -495.65 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
Dyne Therapeutics Inc | 0.00 | -257.40m | 2.27bn | 143.00 | -- | 4.73 | -- | -- | -3.97 | -3.97 | 0.00 | 5.49 | 0.00 | -- | -- | 0.00 | -63.48 | -52.81 | -67.12 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
Myriad Genetics, Inc. | 753.20m | -263.30m | 2.28bn | 2.70k | -- | 2.90 | -- | 3.03 | -3.20 | -3.20 | 9.09 | 8.71 | 0.6423 | 11.22 | 6.98 | 278,963.00 | -22.45 | -- | -25.66 | -- | 68.64 | -- | -34.96 | -- | 1.87 | -342.25 | 0.0469 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
Geron Corp | 520.00k | -201.40m | 2.30bn | 141.00 | -- | 6.60 | -- | 4,425.68 | -0.3464 | -0.3464 | 0.0009 | 0.5876 | 0.0012 | -- | 0.3225 | 3,687.94 | -44.41 | -51.32 | -54.44 | -64.90 | -- | -- | -38,729.81 | -19,949.13 | -- | -- | 0.1935 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
Vera Therapeutics Inc | 0.00 | -94.30m | 2.30bn | 51.00 | -- | 6.52 | -- | -- | -2.04 | -2.04 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -29.99 | -- | -31.92 | -- | -- | -- | -- | -- | -- | -- | 0.124 | -- | -- | -- | -7.79 | -- | -- | -- |
Rhythm Pharmaceuticals Inc | 91.93m | -273.87m | 2.35bn | 226.00 | -- | 38.11 | -- | 25.54 | -4.62 | -4.62 | 1.57 | 1.01 | 0.3042 | 1.53 | 8.06 | 406,747.80 | -90.64 | -47.21 | -108.65 | -52.84 | 88.37 | -- | -297.93 | -681.38 | 4.20 | -139.42 | 0.6355 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
Vericel Corp | 207.78m | 451.00k | 2.36bn | 314.00 | 5,088.91 | 10.09 | 437.87 | 11.38 | 0.0096 | 0.0096 | 4.35 | 4.82 | 0.6684 | 4.38 | 4.71 | 661,719.80 | 0.1451 | -3.07 | 0.1621 | -3.50 | 69.50 | 67.87 | 0.2171 | -4.49 | 4.83 | -- | 0.0007 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
Kymera Therapeutics Inc | 79.41m | -154.59m | 2.37bn | 186.00 | -- | 3.33 | -- | 29.83 | -2.50 | -2.50 | 1.29 | 11.59 | 0.1072 | -- | 29.69 | 424,668.40 | -20.86 | -23.03 | -22.67 | -27.64 | -- | -- | -194.67 | -207.82 | -- | -- | 0.0032 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
Guardant Health Inc | 563.95m | -479.45m | 2.37bn | 1.78k | -- | 14.90 | -- | 4.20 | -4.28 | -4.28 | 5.04 | 1.30 | 0.3321 | 4.00 | 6.06 | 317,002.80 | -28.23 | -22.26 | -31.99 | -24.59 | 59.74 | 64.62 | -85.02 | -97.07 | 6.24 | -12.04 | 0.8778 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
PTC Therapeutics, Inc. | 927.56m | -579.22m | 2.38bn | 988.00 | -- | -- | -- | 2.57 | -7.69 | -7.69 | 12.28 | -11.66 | 0.5459 | 2.33 | 4.64 | 938,823.90 | -34.09 | -26.71 | -48.63 | -33.46 | 92.88 | 93.94 | -62.45 | -83.80 | 1.98 | -0.7975 | 1.72 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
Intellia Therapeutics Inc | 52.60m | -485.50m | 2.40bn | 526.00 | -- | -- | -- | 45.58 | -5.37 | -5.37 | 0.5827 | -- | -- | -- | -- | 100,007.60 | -- | -31.34 | -- | -34.53 | -- | -- | -922.94 | -654.71 | -- | -- | -- | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
Maravai Lifesciences Holdings Inc | 274.10m | -131.04m | 2.48bn | 650.00 | -- | -- | -- | 9.06 | -0.9917 | -0.9917 | 2.08 | -- | -- | -- | -- | 421,690.80 | -- | 12.67 | -- | 15.46 | 44.03 | 74.79 | -58.27 | 37.32 | -- | -2.02 | -- | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
ACADIA Pharmaceuticals Inc | 813.81m | -1.71m | 2.51bn | 610.00 | -- | 5.41 | 280.94 | 3.09 | -0.0129 | -0.0129 | 4.93 | 2.81 | 1.08 | 1.85 | 10.13 | 1,363,159.00 | -0.2264 | -27.50 | -0.3579 | -32.73 | 92.27 | 95.62 | -0.2101 | -38.35 | 1.86 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
Twist Bioscience Corp | 277.49m | -192.14m | 2.52bn | 919.00 | -- | 4.49 | -- | 9.06 | -3.35 | -3.35 | 4.83 | 9.63 | 0.3565 | 4.87 | 7.04 | 301,943.40 | -24.68 | -30.50 | -27.12 | -33.84 | 38.29 | 36.02 | -69.24 | -113.33 | 5.06 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
Holder | Shares | % Held |
---|---|---|
RA Capital Management LPas of 31 Dec 2023 | 46.20m | 8.46% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 38.04m | 6.97% |
Deep Track Capital LPas of 31 Dec 2023 | 29.58m | 5.42% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 27.41m | 5.02% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 25.63m | 4.69% |
Millennium Management LLCas of 31 Dec 2023 | 14.73m | 2.70% |
Geode Capital Management LLCas of 31 Dec 2023 | 10.94m | 2.00% |
Morgan Stanley & Co. LLCas of 31 Dec 2023 | 10.30m | 1.89% |
Wellington Management Co. LLPas of 31 Dec 2023 | 9.48m | 1.74% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 7.03m | 1.29% |